CASP3 and neoplasm: The tracer was also evaluated in a colo205 tumor model treated with the death receptor 5 (DR5)-targeted antibody M413, showing a 1.5-fold higher tracer uptake in tumors with high caspase-3 activity compared to tumors with low caspase-3 activity, with an absolute value of 1.2%ID/cc [37].